皇冠環球(00727.HK)擬發共5億人幣票據及CB 發展墓園業務
皇冠環球(00727.HK)公布,全資附屬冠紅亞太與合作方簽訂意向書,合作方旗下的鎮江禮儀將收購兩家殯儀服務及墓園管理公司帽山陵園與嘉山置業,而皇冠環球則計劃發行3億元人民幣(下同)票據及2億元可換股債券,所得部分資金將以冠紅亞太向鎮江禮儀借款的形式用於收購上述兩公司100%股權。
完成收購兩公司後,冠紅亞太將以1元代價購入鎮江禮儀60%股權,雙方並將合作發展墓園項目規劃建設、康養小鎮及墓地地宮銷售、日常營運管理等。根據意向書,鎮江禮儀將借款本金及約定回報收益全數返還冠紅亞太後,涉及的60%股權將以1元之代價售回給合作方。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.